FDA leadership in crisis — multiple outlets report Trump will fire Commissioner Makary after 14 turbulent months. Leqembi SC review extended three months to August 24. Bayer acquires Perfuse for $2.45B; Daiichi Sankyo takes $610M ADC manufacturing hit; Gilead targets $1B in Yeztugo sales.Visit us at www.thepharmcloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Marty Makary, Trump, Leqembi, lecanemab, Eisai, Biogen, Bayer, Perfuse Therapeutics, glaucoma, Daiichi Sankyo, ADC, Enhertu, Gilead, Yeztugo, lenacapavir, PrEP, HIV, Bizengri, zenocutuzumab, CNPV, Partner Therapeutics, Artiva, rheumatoid arthritis, Odyssey Therapeutics, IPO, Entrada, Capricor, Duchenne, DMD, Angelini, Catalyst, Argenx, Vyvgart, Novo Nordisk, Wegovy, Sarepta, Lilly, Sanofi
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →